MannKind Corp Earnings

The next earnings date for MannKind Corp is November 11, 2025.

They are scheduled to announce earnings after the market closes that day.

Analyst Estimates of MannKind Corp Earnings

Report DateEstimated Earnings Per Share
11/11/2025$0.05

What is an Earnings Date

An earnings date is typically considered to be the date that a company publicly announces its earnings. Many companies in the US stock market do earnings announcements once per quarter.

Earnings announcements are typically accompanied by commentary from the company that explains the earnings performance and speaks to future earnings prospects.

Earnings announcements can cause a company’s stock price to change abruptly, so earnings dates are closely monitored by some investors.

MannKind Corp Earnings: Historical

Report DateBefore/After MarketEarnings Per ShareSurprise %
08/06/2025---$0.050.00%
05/06/2025Before Market$0.04-33.33%
02/25/2025Before Market$0.03---
11/07/2024After Market$0.0566.67%
08/07/2024Before Market$-0.01-200.00%
05/08/2024After Market$0.0433.33%
02/27/2024After Market$0.00-57.00%
11/07/2023After Market$0.01150.00%
08/07/2023After Market$-0.0250.00%
05/09/2023After Market$-0.0420.00%
02/22/2023Before Market$-0.07-16.67%
11/08/2022Before Market$-0.0633.33%
08/09/2022After Market$-0.11-22.22%
05/05/2022After Market$-0.100.00%
02/24/2022After Market$-0.11-57.14%
11/09/2021After Market$-0.0271.43%
08/11/2021After Market$-0.05-25.00%
05/12/2021After Market$-0.05-25.00%
02/25/2021Before Market$-0.06-50.00%
11/04/2020After Market$-0.050.00%
08/05/2020After Market$-0.050.00%
05/06/2020After Market$-0.0433.33%
02/25/2020Before Market$-0.070.00%
11/06/2019Before Market$-0.0537.50%
08/07/2019After Market$-0.070.00%
05/07/2019Before Market$-0.0820.00%
02/26/2019Before Market$-0.06-127.27%
11/01/2018Before Market$-0.1611.11%
08/02/2018After Market$-0.1620.00%
05/09/2018After Market$-0.25-8.70%
02/27/2018After Market$-0.283.45%
11/07/2017After Market$-0.31-55.00%
08/07/2017After Market$-0.35-40.00%
05/10/2017After Market$-0.17-112.50%
03/16/2017After Market$-0.195.00%
11/09/2016Before Market$1.30564.29%
08/08/2016After Market$-0.35-9.38%
05/09/2016After Market$-0.30-42.86%
03/14/2016After Market$-0.85-226.92%
11/09/2015Before Market$-0.40-17.65%
08/10/2015Before Market$-0.3510.26%
05/07/2015After Market$-0.404.76%
02/24/2015After Market$-0.452.17%
11/03/2014Before Market$-0.45-1,600.00%
08/11/2014---$-0.95-61.02%
05/12/2014---$-0.70-9.38%
02/18/2014---$-0.80-15.94%
11/04/2013---$-0.85-19.72%
08/09/2013---$-0.80-14.29%
05/09/2013---$-0.752.60%
02/11/2013---$-1.15-29.21%
11/01/2012---$-1.105.98%
08/07/2012---$-1.158.73%
05/09/2012---$-1.35-19.47%
02/22/2012---$-1.505.66%
11/03/2011---$-1.552.52%
08/04/2011---$-1.85-18.59%
05/09/2011---$-1.70-18.06%
02/10/2011---$-1.6518.32%
10/29/2010---$-2-3.09%
08/02/2010---$-1.857.96%
04/30/2010---$-28.26%
02/01/2010---$-2.65-31.84%
11/02/2009---$-2.1013.22%
08/03/2009---$-2.703.23%
05/04/2009---$-2.9012.39%
02/17/2009---$-4.10-26.54%
11/05/2008---$-3.3515.83%
08/11/2008---$-3.95-6.47%
05/05/2008---$-3.5011.17%
03/04/2008---$-3.754.09%
11/07/2007---$-4.959.34%
08/09/2007---$-4.906.67%
05/11/2007---$-5-0.60%
02/02/2007---$-6.50-6.04%
11/02/2006---$-6.15-4.95%
08/03/2006---$-5.50-21.68%
05/05/2006---$-4.35-18.21%
02/06/2006---$-3.30-8.20%
10/24/2005---$-3.65-18.12%
07/28/2005---$-4.15-6.96%
05/06/2005---$-3.4020.19%
02/03/2005---$-3.2518.34%
11/03/2004---$-7-93.91%
09/01/2004---$-1.52---

More About MannKind Corp

Country
USA
Full Time Employees
403

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of therapeutic products and services for endocrine and orphan lung diseases in the United States. It offers Afrezza Inhalation Powder, an inhaled insulin used to improve glycemic control in adults with diabetes; the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults; and Tyvaso DPI for the treatment of pulmonary arterial hypertension and pulmonary hypertension. The company's product pipeline includes MNKD-101, a nebulized formulation of clofazimine, which is in Phase 3 study, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, which is in phase 1 clinical study, for the treatment of idiopathic pulmonary fibrosis (IPF); MNKD-301, which is in preclinical stage, for cystic fibrosis; and Pediatric Afrezza, which is in phase 3 clinical trial for the treatment of diabetes mellitus. It has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India; and co-promotion agreement with Amphastar for marketing of Baqsimi (glucagon) nasal powder. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.

MannKind Corp Earnings” Can Refer to the MannKind Corp Earnings Date

Some people say “MannKind Corp earnings” as a shortform way to refer to the earnings date.

For example, someone might say, “I plan to hold my MannKind Corp position through earnings.” That typically means the person is going to hold their position through the upcoming earnings date.

Owning MannKind Corp Stock on the Earnings Date

If you own MannKind Corp stock (MNKD) on the earnings date, then you will be exposed to the potential price volatility that often accompanies earnings announcements.

A company’s earnings typically have a big impact on its stock price, which explains why the stock price for MannKind Corp might exhibit major fluctuations on the day of the earnings announcement. The price fluctuations can go in either direction (up or down), representing a larger potential investment risk and reward than many other days of the year.

There is often a big audience of investors involved with trading MannKind Corp shares of stock on its earnings day. This means there is typically more trading volume, liquidity, and price volatility on the day earnings are announced.

These features are attractive to some types of active traders who are looking for stocks that exhibit large price movements and substantial volume.

Owning MannKind Corp Options on the Earnings Date

If you own MannKind Corp options on the earnings date, then you will be exposed to the potential price volatility that often accompanies earnings announcements.

In addition, the extrinsic values of MannKind Corp options that overlap earnings dates are often higher than other days of the year. In other words, the premiums you pay to own MannKind Corp options are typically higher during that period. In particular, they are frequently higher immediately before earnings and on the day they’re announced.

This makes sense considering that prices are often more volatile on earnings dates for MannKind Corp. That potential volatility is a key factor that affects the premium cost of owning options.

Once the earnings announcement is done and the anticipated price volatility has gone down, the extrinsic values of MannKind Corp options often go down. This is sometimes referred to as volatility crush.

Learning More MannKind Corp Earnings

You can contact us any time if you would like to ask questions about MannKind Corp earnings or anything else related to the stock market.

This site uses cookies to provide you with an optimal user experience. By using StockMarketGuides.com, you accept our use of cookies.